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Abstract
Liver cirrhosis is often complicated by an impaired renal excretion of water and sodium. Diuretics tend to further deteriorate
renal function. It is unknown whether chronic selective adenosine A1 receptor blockade, via inhibition of the hepatorenal
reflex and the tubuloglomerular feedback, might exert diuretic and natriuretic effects without a reduction of the glomerular
filtration rate. In healthy animals intravenous treatment with the novel A1 receptor antagonist SLV329 resulted in a strong
dose-dependent diuretic (up to 3.4-fold) and natriuretic (up to 13.5-fold) effect without affecting creatinine clearance. Male
Wistar rats with thioacetamide-induced liver cirrhosis received SLV329, vehicle or furosemide for 12 weeks. The creatinine
clearance of cirrhotic animals decreased significantly (236.5%, p,0.05), especially in those receiving furosemide (241.9%,
p,0.01). SLV329 was able to prevent this decline of creatinine clearance. Mortality was significantly lower in cirrhotic
animals treated with SLV329 in comparison to animals treated with furosemide (17% vs. 54%, p,0.05). SLV329 did not
relevantly influence the degree of liver fibrosis, kidney histology or expression of hepatic or renal adenosine receptors. In
conclusion, chronic treatment with SLV329 prevented the decrease of creatinine clearance in a rat model of liver cirrhosis.
Further studies will have to establish whether adenosine A1 receptor antagonists are clinically beneficial at different stages
of liver cirrhosis.
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Introduction
Liver cirrhosis is often complicated by an impaired renal
capacity of maintaining water and sodium balance. Splanchnic
arterial vasodilatation due to an increased release of endogenous
vasodilators leads to compensatory activation of the endogenous
vasoconstrictor systems: the sympathetic nervous system, the
renin-angiotensin system and the non-osmotic release of vasopres-
sin [1]. This causes renal sodium/water retention and renal
vasoconstriction eventually leading to the hepatorenal syndrome.
In many patients, water retention can be controlled by sodium
restriction and diuretics. However, diuretic therapy often entails
deterioration of renal function [1]. There is an urgent clinical need
for alternative pharmacological approaches.
The adenosine system with its four receptors (A1,A 2A,A 2B and
A3) is involved in several key functions of both liver and kidneys
[2]. Decreasing the portal flow, as it is the case in cirrhosis, results
in an activation of the hepatic adenosine system [3]. Adenosine,
via A1 receptors (A1R), serves as a mediator for triggering the
hepatorenal reflex leading to renal water and sodium retention
[4,5]. However, the exact localization of adenosine receptors
within the liver remains unclear. In the kidney A1R are highly
expressed in the preglomerular microcirculation, but also on the
proximal tubules and other renal structures [6]. Short-term
infusion of selective A1R antagonists inhibits the tubuloglomerular
feedback and causes diuresis and natriuresis [7,8]. Blockade of
hepatic and renal A1R could therefore provide a new therapeutic
option in conditions with sodium and water retention such as liver
cirrhosis [9].
Thioacetamide has been widely used to induce chronic liver
injury in animal models since it mimics the human disease closely.
Rats treated with thioacetamide present with typical cirrhotic liver
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[10].
The first part of the present study evaluated the receptor
binding affinity of the novel adenosine A1R antagonist SLV329 - a
pyrimidine derivative - and confirmed its in vivo action on diuresis
and natriuresis in healthy animals. As main hypothesis of this
study, we tested whether SLV329 might exert diuretic effects
without impairing renal function in animals with thioacetamide-
induced liver cirrhosis.
Results
In vitro selectivity profile of SLV329
In receptor binding experiments using cloned human receptors
SLV329 behaved as a potent (pKi 9.2) and selective A1R ligand.
The affinity of SLV329 for the other adenosine receptors was at
least 100-fold lower (Table 1). The receptor-binding affinities and
enzyme inhibitory properties of SLV329 were evaluated in a series
of 94 receptors and 6 phosphodiesterases including adenosine
transporters and a wide range of adrenergic, muscarinic, nicotinic,
dopaminergic, serotoninergic, histaminergic, glutamatergic, opi-
oid, angiotensin, bradykinin and neuropeptide receptors as well as
ion channels and transporter sites. Only the significant affinities of
SLV329 are summarized in Table 1. Apart from adenosine
receptors, significant binding was measured only for the high-
affinity rolipram-binding site on phosphodiesterase 4. This effect
was consistent with the inhibition of this enzyme by SLV329.
However, phosphodiesterase 4 inhibition was much less potent
than A1R binding. The ratio of the Ki value for phosphodiesterase
4 inhibition by SLV329 to that of the A1R binding was 3170. The
activities on other phosphodiesterases were at least 10-fold lower.
The half-maximally inhibitory concentration (IC50) value of
SLV329 is 3.2 mg/l.
Effects of SLV329 on renal function in healthy rats
Five different intravenous doses of SLV329 were tested in
healthy anesthetized rats. Table 2 shows that SLV329 treatment
resulted in a marked dose-dependent increase of diuresis by up to
3.4-fold and sodium excretion by up to 13.5-fold compared to the
time-matched vehicle control group (both p,0.0001). The half-
maximally effective concentration (EC50) values for diuresis and
natriuresis were calculated to be 26 mg/l and 17 mg/l respectively.
In contrast, the rate of potassium excretion was only modestly
affected (up to only 1.7-fold vs. vehicle). The creatinine clearance
was not affected by SLV329, even at the highest dose. SLV329
caused a dose-dependent increase in urinary adenosine excretion
by up to 4.2-fold.
Effects of SLV329 on renal function in thioacetamide-
induced liver cirrhosis
Descriptive data, results from histological evaluation and
Western blots are summarized in Table 3. Representative
immunoblots for hepatic and renal adenosine receptors are shown
in Figure 1. The results of plasma and urine analyses are shown in
Table 4.
Livers of the thioacetamide-treated rats showed macroscopic
signs of nodular cirrhosis and tended to be heavier than livers from
control groups. While liver fibrosis was seen in thioacetamide-
treated rats (p,0.001), kidney histology showed no relevant
alterations in any of the groups. During the development of liver
cirrhosis bilirubin rose markedly, whereas there was a significant
decrease of plasma albumin. There was no relevant amount of
ascites in any of the cirrhotic groups.
Bodyweight (p,0.001) and water intake (p,0.01) was lower in
rats treated with thioacetamide as compared to control animals.
Furosemide and SLV329 caused an increase of mean water intake
(probably reflecting increased diuresis), particularly at the
beginning of the treatment (e.g. week 11, p,0.05; Table 3).
Plasma creatinine was reduced in all cirrhotic animals, most
probably due to reduced muscle mass because of wasting. Plasma
creatinine was significantly lower in the SLV329-treated groups, in
spite of higher mean body weight. The creatinine clearance was
significantly reduced in cirrhotic animals compared to controls
(236,5%, p,0.05; Figure 2). This was even slightly more
pronounced in the group treated with furosemide (241.9%,
p,0.01 compared to controls). In contrast, the creatinine
clearance of the cirrhotic group treated with SLV329 did not
differ significantly from any of the non-cirrhotic groups.
The reduction of mortality in cirrhotic animals treated with
SLV329 compared to untreated cirrhotic animals did not reach
statistical significance. However, mortality was significantly lower
compared to cirrhotic animals treated with furosemide (17% vs.
54%, p,0.05; Figure 3).
In the Western blot analyses hepatic A2R seemed to be reduced
in cirrhotic rats. This difference was statistically significant for
A2AR and A2BR when testing all cirrhotic rats vs. all controls
(p,0.01). Treatment with SLV329 reduced A1R expression in
renal tissue of non-cirrhotic animals (p,0.01).
Mean plasma concentrations of SLV329 were 4968 mg/l on
day 10 after the beginning of SLV329 treatment and 54613 mg/l
after 4 weeks in 6 random animals.
Heart rate, lipase, creatine kinase and urinary protein excretion
were not different between the groups at any time (data not
shown).
Discussion
The present study was set out to investigate the receptor binding
affinity of the novel A1R antagonist SLV329, to evaluate its in vivo
effects on diuresis and natriuresis in healthy animals and to find
out whether it exerts beneficial effects in an animal model of
thioacetamide-induced liver cirrhosis.
Receptor binding experiments showed that SLV329 behaves as
a potent and selective A1R ligand in vitro.
Table 1. Receptor binding affinities and enzyme inhibitory
properties of SLV329.
Assay Cell/tissue Ligand
SLV329
Affinity
Adenosine A1 CHO cells
3H-DPCPX 9.260.2
Adenosine A2A HEK293 cells
3H-CGS21680 7.260.2
Adenosine A3 HEK293 cells
3H-AB-MECA 6.960.1
Adenosine A2B HEK293 cells
3H-DPCPX 6.360.1
Phosphodiesterase
4 rolipram binding
Total brain
3H-Rolipram 6.160.2
Phosphodiesterase 4 enzyme U-937 cells
3H-cAMP 5.460.1
Phosphodiesterase 6 enzyme Retina
3H-cAMP 4.360.1
Only significant affinities and enzyme inhibition of SLV329 are shown.
Cells and tissues used to obtain receptors/enzymes and radioactive ligands of
the respective assays are listed. Cells and tissues were provided by Cerep (Celle
l’Evescault, France)
Results are expressed as pKi for radioligand affinity assays, and as pIC50 for
enzyme inhibition. Mean 6 standard deviation of at least 3 determinations.
doi:10.1371/journal.pone.0017891.t001
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strong dose-dependent diuretic and natriuretic effect, whereas the
effect on kaliuresis was relatively small and the creatinine clearance
remained unchanged. This is in line with effects that have been
reported in a variety of rat strains including Wistar rats [11–13].
The ability of diuretics to prevent sodium reabsorption results in
an increased delivery of electrolytes to the distal tubule. This leads,
in turn, to an augmented release of adenosine, which may activate
A1R in afferent arterioles [14]. By blocking those receptors, A1R
antagonists cause an uncoupling of the tubuloglomerular feedback
which may at least partly explain the elevated concentrations of
adenosine measured in the urine of animals treated with SLV329
[15,16]. However, urinary excretion of paracrine mediators do not
necessarily reflect their local tissue concentrations. Alternatively,
blockade of A1R might result in elevated intracellular cyclic
adenosine monophosphate levels and release in the kidney, which
will eventually lead to increased extracellular adenosine concen-
trations due to cyclic adenosine monophosphate degradation [17–
19]. However, in spite of the observed increase in urinary
adenosine excretion, SLV329 did not decrease the rate of
creatinine clearance, even at the highest dose.
Previous studies demonstrated that a single application of an
A1R antagonist causes an increase of renal sodium and water
excretion in animals and patients with liver cirrhosis without
affecting the glomerular filtration rate [20,21]. As a next step
towards a possible clinical application, the present study
investigated for the first time the effects of a chronic application
of a selective A1R antagonist on kidney function and mortality
starting at an early stage of liver cirrhosis. This proof-of-concept
experiment included a low-dose furosemide-treated group because
loop diuretics are often applied in cirrhotic patients and tend to
deteriorate renal function. However, monotherapy with a loop
diuretic is of course not the typical clinical situation at an early
stage of liver cirrhosis without severe water retention. In the
present study the creatinine clearance, used as a surrogate for the
glomerular filtration rate, was significantly reduced in cirrhotic
animals, especially in those receiving furosemide. In contrast, the
A1R antagonist SLV329 was able to prevent this decline of
creatinine clearance. The reduction of mortality in cirrhotic
animals treated with SLV329 in comparison to vehicle treatment
was not statistically significant. However, mortality was signifi-
cantly lower in cirrhotic animals treated with SLV329 in
comparison to animals treated with furosemide (17% vs. 54%).
It is a limitation of this study that creatinine clearance was used
instead of inulin clearance. Inulin clearance was not used because
mortality would have increased further due to additional
anesthesia. Creatinine clearance is influenced by muscle mass,
liver function and tubular secretion of creatinine. However, there
were no significant differences of neither body weight nor liver
function between cirrhotic animals with and without SLV329
treatment. Tubular secretion of creatinine increases with declining
glomerular filtration rate. Thus, the glomerular filtration rate of
untreated cirrhotic animals and those treated with furosemide will
be even lower than the creatinine clearance suggests, making the
difference to the group treated with SLV329 even larger.
Mean SLV329 plasma concentrations of 49–54 mg/l were
actually reached by chronic application in the cirrhosis model.
This plasma concentration was able to cause strong short-term
effects on diuresis and saliuresis when administered intravenously as
shown in Table 2. A steady-state is usually reached in the course of
long-term diuretic therapy by means of compensatory mechanisms
of tubular reabsorption [22]. This explains why the 24-hour urine
volume and electrolyte excretion in week 16 is not different between
the groups of the cirrhosis model. However, when looking at mean
water intake over 8 weeks, as a putative surrogate of diuresis, the
effects of furosemide and SLV329 can be detected. It would have
been interesting to evaluate fractional sodium excretion and free
waterclearance.Thiswasnot doneduetolimited plasmaquantities.
SLV329 does not affect the expression of hepatic or renal
adenosine receptors in cirrhotic animals. The expression of A2R
Table 2. Effects of different doses of SLV329 in anesthetized rats.
SLV329 bolus (mg/kg) Vehicle 18 54 180 540 945
infusion (mg/kg*min) Vehicle 0.37 1.1 3.7 11 19.3
Plasma SLV329 (mg/l) 0601 1 62.6 3164.4 54612 86621 182663
Diuresis (fold vs. vehicle) 160.1 1.460.1* 2.560.3**** 2.360.3*** 3.460.4**** 2.860.4****
Diuresis (ml/kg*h) 160.1 1.460.1* 2.560.3**** 2.360.3*** 3.460.4**** 2.860.4****
Natriuresis (fold vs. vehicle) 160.2 5.060.8*** 7.660.9**** 7.961.3**** 13.561.3**** 8.361.4****
Natriuresis (mg/kg*h) 65616 324652*** 497662**** 518684**** 882687**** 544694****
Kaliuresis (fold vs. vehicle) 160.1 1.660.2 1.460.1 1.760.1** 1.360.1 1.660.2
Kaliuresis (mg/kg*h) 106613 167621 146613 175616** 136612 170622
Creatinine clearance (ml/min) 1.960.3 3.261.1 2.060.3 1.660.2 2.660.8 2.460.7
Adenosine excretion (nmol/h) 2.460.7 3.160.4* 4.960.8** 5.961.5* 10.262.3*** 9.861.9***
Body weight (g) 363633 6 0 623 5 6 63 36262 364623 5 7 62
Systolic blood pressure (mmHg) 107661 0 8 621 0 4 63 11065 113671 1 6 66
Heart rate (beats/min) 313619 317623 328621 350610 294623 301630
A bolus of SLV329 followed by an intravenous infusion over 3 hours produces a strong dose-dependent stimulation of renal water, sodium and adenosine excretion
without any effect on creatinine clearance. Diuresis and electrolyte excretion is expressed as fold stimulation vs. time-matched vehicle controls.
Data are means 6 standard error of the mean.
n=9-13 animals per dose.
*p,0.05,
**p,0.01,
***p,0.001,
****p,0.0001 vs. time-matched vehicle controls.
doi:10.1371/journal.pone.0017891.t002
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treatment group. As yet, there are no reports on the expression of
A2R in cirrhotic liver tissue. However, it is known, that hepatic
A2R play an active role in the pathogenesis of hepatic fibrosis [23].
It is a limitation of this study that adenosine receptor expression
was evaluated only in liver and kidney homogenates by Western
blot. Immunohistochemistry or radioligand binding experiments
might give further detailed information.
The beneficial effects of SLV329 in the cirrhosis model cannot
be explained by morphological effects since SLV329 did not
relevantly influence the degree of liver fibrosis, kidney histology or
expression of hepatic or renal adenosine receptors. Animal studies
suggest that liver cirrhosis activates the hepatorenal reflex via A1R,
leading to renal water and sodium retention [24,25]. Animal and
human studies suggest that a resetting of the tubuloglomerular
feedback contributes to the pathophysiology of kidney impairment
in liver cirrhosis [26]. Thus, inhibition of both the hepatorenal
reflex and the tubuloglomerular feedback might explain the higher
rate of creatinine clearance in the animals treated with SLV329. In
addition to the effect on creatinine clearance, yet unknown effects
of SLV329 might contribute to the reduction of mortality. As an
addition to the present study it would be interesting to study liver
cirrhosis in the established murine A1R knockout model.
The ability of A1R antagonists to induce diuresis and natriuresis
while not compromising glomerular filtration rate has become an
attractive therapeutic option for the treatment of other fluid
retention disorders, e.g. in kidney disease and heart failure,
especially in conditions associated with diuretic resistance [27].
The preexisting experience with this class of drugs for other
indications (includinga large phase 3 trial) might facilitate the future
translation of the results of this study to clinical application [28].
In conclusion, this study described some pharmacodynamic
characteristics of the novel adenosine A1R-specific antagonist
SLV329 and demonstrated its long-term safety and efficacy in an
animal model of liver cirrhosis. Chronic SLV329 treatment
starting at an early stage of liver cirrhosis prevented the decrease
of creatinine clearance. Further studies will have to evaluate,
whether SLV329 or other A1R antagonists are clinically beneficial
at different stages of liver cirrhosis, either as an add-on to
aldosterone antagonists or in combination with loop diuretics.
Materials and Methods
Receptor binding and enzyme assays
Receptor binding affinities as well as enzyme inhibitory
properties of the new compound SLV329 were evaluated in a
Table 3. Effects of treatment with furosemide and SLV329 in rats with and without liver cirrhosis.
Group Con Con+Fur Con+SLV Cir Cir+Fur Cir+SLV
Bodyweight week 0 (g) 358663 4 4 610 356611 35166 354663 5 2 65
Bodyweight week 8 (g) 443611 433613 439615 33368*** 34566*** 33565***
Bodyweight week 16 (g) 464611 448610 479616 29969*** 263613*** 29669***
#
Water intake week 0–8 (ml/kg*d) 41644 7 644 0 654 9 62* 46615 0 62
Water intake week 8–16 (ml/kg*d) 65626 9 627 0 644 4 62*** 5262***
1 5062**
1
Water intake week 11 (ml/kg*d) 63647 6 65
1 7263
11 4862** 5262** 5464**
1
Systolic BP week 0 (mmHg) 124621 2 6 66 13063 12661 125621 2 7 62
Systolic BP week 12 (mmHg) 122631 1 9 65 13467
1 11065 118651 1 8 63*
Liver weight (g) 12.560.5 11.960.5 13.260.7 13.960.5 13.460.5* 14.160.3
Kidney weight (g) 3.160.1 3.060.1 3.260.1 3.160.1 3.060.1 2.960.1
Liver interstitial fibrosis (%) 0.360.1 0.460.1 0.960.3 8.661.1*** 5.261.1*** 8.661.4***
Kidney interstitial fibrosis (%) 3.060.3 3.460.6 3.560.6 2.960.3 3.160.6 3.260.4
Kidney media/lumen ratio 3.360.4 3.160.2 2.660.3 2.660.2 2.860.2 3.060.3
Glomerulosclerosis index (0–4) 1.860.04 1.860.1 1.660.1 1.760.05 1.760.1 1.860.1*
Liver A1 receptor 1.060.1 1.060.2 1.160.1 0.860.1 1.060.1 1.060.1
Liver A2A receptor 1.060.2 1.260.1 0.960.1 0.760.1 0.860.1 0.860.1
Liver A2B receptor 1.060.2 1.060.3 0.760.1 0.460.1* 0.660.1 0.660.1
Liver A3 receptor 1.060.2 0.760.1 0.960.2 0.860.2 1.060.2 0.860.1
Kidney A1 receptor 1.060.03 1.060.2 0.660.1
11 0.860.1* 0.860.1 0.760.1
Kidney A2A receptor 1.060.1 0.960.2 1.060.1 0.960.2 1.260.2 1.260.1
Kidney A2B receptor 1.060.1 0.960.2 1.460.2 1.360.2 1.360.1 1.060.2
Kidney A3 receptor 1.060.1 0.760.2 0.860.2 0.760.1 1.260.2 0.960.3
Con, control; Cir, liver cirrhosis; Fur, furosemide; SLV, SLV329, BP, blood pressure.
Results of adenosine receptors from Western blots are expressed as fold expression vs. Con.
Data are means 6 standard error of the mean. n=8–14 per group.
*p,0.05,
**p,0.01,
***p.0.001 vs. Con group with same treatment,
1p,0.05,
11p,0.01 vs. same group without Fur or SLV treatment,
#p,0.05 vs. same group with Fur treatment.
doi:10.1371/journal.pone.0017891.t003
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17891Figure 1. Representative immunoblots for hepatic and renal adenosine A1,A 2A,A 2B and A3 receptors. Beta-actin was used for
normalization before statistical analysis. Con, control; Cir, liver cirrhosis; Fur, furosemide; SLV, SLV329; kDa, kilodalton.
doi:10.1371/journal.pone.0017891.g001
Table 4. Effects of treatment with furosemide and SLV329 on plasma and urine parameters in rats with and without liver cirrhosis.
Group Con Con+Fur Con+SLV Cir Cir+Fur Cir+SLV
ALT week 8 (U/l) 26633 6 652 9 644 1 662 7 63*
1 3164
ALT week 16 (U/l) 55644 8 624 7 647 3 696 6 611 5367
Bilirubin week 8 (mmol/l) 1.360.1 1.560.3 1.460.2 7.360.7*** 6.060.8*** 5.760.9***
Bilirubin week 16 (mmol/l) 1.260.3 1.560.4 1.360.3 1661.8*** 2262.9*** 1262.0***
#
Albumin week 8 (g/l) 3160.4 3260.4 3160.2
# 3160.5 3260.5 3160.4
Albumin week 16 (g/l) 2960.5 2960.7 2860.3
# 2660.6** 2561.0* 2660.5***
Creatinine week 8 (mmol/l) 52625 4 635 4 635 5 625 2 624 9 61
1
Creatinine week 16 (mmol/l) 60616 0 625 5 61
11# 5162* 4762** 4562**
1
Urine volume week 8 (ml/d) 51665 9 645 2 685 8 636 1 636 5 65
Urine volume week 16 (ml/d) 71687 5 636 7 696 7 685 8 666 9 67
Na
+ excretion week 8 (mmol/d) 3.260.5 3.160.2 2.960.5 3.660.5 3.760.4 2.960.3
Na
+ excretion week 16 (mmol/d) 3.760.6 5.560.5 4.460.6 4.760.6 3.860.9 4.160.3
K
+ excretion week 8 (mmol/d) 4.460.6 5.060.5 4.360.5 4.460.5 4.860.4 4.360.4
K
+ excretion week 16 (mmol/d) 7.660.6 7.760.8 6.760.7 6.260.6 5.060.7 7.060.4
Con, control; Cir, liver cirrhosis; Fur, furosemide; SLV, SLV329.
In week 0, there were no significant differences between the groups, except for plasma creatinine (Con+Fur 4666 vs. Cir+Fur 5365 mmol/l; p,0.05) and urine volume
(Con+Fur 70616 vs. Cir+Fur 5866 ml/d; p,0.05).
Data are means 6 standard error of the mean. n=8–14 per group.
*p,0.05,
**p,0.01,
***p.0.001 vs. Con group with same treatment,
1p,0.05,
11p,0.01 vs. same group without Fur or SLV treatment,
#p,0.05 vs. same group with Fur treatment.
doi:10.1371/journal.pone.0017891.t004
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previously [29]. All cells and tissues needed for the assays were
provided by Cerep (Celle l’Evescault, France).
Receptor binding assays were conducted as follows: after
incubation of SLV329 with a receptor preparation and its
radioactive ligand, the receptor preparations were rapidly filtered
under vacuum through glass fiber filters, the filters were washed
extensively with an ice-cold buffer using a harvester. Bound
radioactivity was measured by scintillation counting using a liquid
scintillation cocktail. Enzyme assays were carried out as follows:
after incubation of SLV329 with an enzyme preparation and its
radioactive substrate, radioactivity of the enzyme product was
measured by scintillation counting using a liquid scintillation
cocktail. Testing was done at a 3-log concentration range around a
predetermined half-maximally inhibitory concentration (IC50) for
the respective assay. The highest concentration tested for primes
was 10 mM in receptor binding and 100 mM for enzyme assays. If
no significant receptor binding or enzyme inhibition was detected
at those concentrations SLV329 was considered to be inactive.
Results were calculated as percentage of control values (enzyme
assays) or for receptor binding assays as percentage of total ligand
binding and that of nonspecific binding per concentration of
SLV329. From the concentration-displacement curves IC50 values
were determined by nonlinear regression analysis using Hill
equation curve fitting. The inhibition constants (Ki) were
calculated from the Cheng-Prusoff equation Ki=IC 50/(1+L/Kd),
where L is the concentration of radioligand in the assay and Kd the
affinity of the radioligand for the receptor. Results were expressed
as mean pKi values 6 standard deviation (SD) of at least three
separate experiments.
Effects of SLV329 on renal function in healthy rats
All animal experiments of this study were conducted in strict
accordance with the European Convention for the Protection of
Vertebrate Animals used for Experimental and Other Scientific
Purposes (ETS123) and the German law on animal welfare and all
efforts were made to minimize suffering. The study protocol was
approved by the Niedersa ¨chsisches Landesamt fu ¨r Verbrau-
cherschutz und Lebensmittelsicherheit (Bezirksregierung Hann-
over, approval number 509.6.42502-04/875).
Male Sprague-Dawley Crl:CD(SD)BR rats (150–170 g) were
fasted overnight. The rats were anesthetized with 80 mg/kg
thiobutabarbital intraperitoneally; additional doses of 40 mg/kg
were given 2.5 h and 5 hours later. Catheters were placed in one
jugular vein (for SLV329 or vehicle administration), one carotid
artery (for blood sampling and blood pressure measurements), and
the bladder. The rats were kept on a heated table to maintain body
temperature at 37uC. After an equilibration period of 30 min,
urine was sampled for a period of 3 h, then the animals received
vehicle or SLV329 as follows: a slowly applied (30–60 s) loading
bolus of 18, 54, 180, 540, and 945 mg/kg of SLV329 (in 0.45 ml/
kg), followed by a continuous intravenous infusion at a rate of 0.37,
1.1, 3.7, 11, and 19.3 mg/kg SLV329 per minute (in 9.3 ml/kg per
minute) for three hours. Urine and blood samples were collected
2 min before the SLV329 bolus and after three hours of SLV329
infusion. 5-sulfosalicylic acid was added to the urine aliquots for
adenosine measurements at a final concentration of 8 g/l before
freezing. Electrolytes and creatinine in plasma and urine were
measured by standard automated analyzer by Medizinisches
Labor Hannover (Hannover, Germany). Urine adenosine con-
centrations were quantified by high-pressure liquid chromatogra-
phy using a MZ nucleosil C18 column (12564 mm, 10 mm) with
ultraviolet-detection (Immundiagnostik, Bensheim, Germany).
Quantification of SLV329 plasma concentrations was performed
after solid phase extraction using a validated reversed phase high-
pressure liquid chromatography method with MS/MS-detection
(Sciex Api 3000, Perkin Elmer, Waltham, MA, USA). The data
describing the concentration-dependence of the diuretic and
natriuretic effects of SLV329 were fitted to estimate the half-
Figure 2. Creatinine clearance (week 16) in rats with and
without liver cirrhosis. There were no significant differences
between the groups in week 0 and week 8. In week 16 creatinine
clearance of the cirrhotic SLV329 group was not significantly different
from any of the non-cirrhotic groups. Data are means 6 standard error
of the mean. n=8–10 per group (week 16). *p=0.05, **p,0.01 vs. non-
cirrhotic control rats.
1p=0.07 vs. cirrhotic animals with furosemide
treatment.
doi:10.1371/journal.pone.0017891.g002
Figure 3. Kaplan-Meier mortality chart of rats with liver
cirrhosis (Cir; mortality 5/14), cirrhotic rats with furosemide
treatment (Cir+Fur; 7/13), cirrhotic rats with SLV329 treatment
(Cir+SLV; 2/12) and all control groups without liver cirrhosis
(Con; 0/24). p,0.05 for Cir+Fur vs. Cir+SLV (log-rank test).
doi:10.1371/journal.pone.0017891.g003
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(GraphPad Software Inc., San Diego, CA, USA).
Effects of SLV329 in thioacetamide-induced liver cirrhosis
The study protocol was approved by the Landesamt fu ¨r
Gesundheit und Soziales, Berlin (approval number G0163/06).
Male Wistar rats (250–300 g) were maintained under controlled
conditions (2062uC, 12 h light/dark cycle) and kept on a standard
diet (0.2% sodium) with water ad libitum.
Animals were divided into 6 groups:
1. Controls (Con; n=8)
2. Controls with furosemide treatment (Con+Fur; n=8)
3. Controls with SLV329 treatment (Con+SLV; n=8)
4. Cirrhosis (Cir; n=14)
5. Cirrhosis with furosemide treatment (Cir+Fur; n=13)
6. Cirrhosis with SLV329 treatment (Cir+SLV; n=12)
Liver cirrhosis was induced by oral administration of thioace-
tamide via drinking water for 18 weeks. The initial concentration
was 0.03%. This concentration was modified weekly according to
weight changes in response to thioacetamide. The concentration
was increased/reduced by 0.015% (absolute) in case of weight
gain/loss .25 g per week. Treatment with furosemide or SLV329
was started in week 8, since it is known that liver cirrhosis develops
by then [30]. Thioacetamide concentrations remained unchanged
from week 8 until week 12. In week 12 the concentration was
increased by 0.015% in all animals receiving thioacetamide. The
resulting concentration was given until week 18. Furosemide was
injected intraperitoneally (7.5 mg/kg) thrice weekly (always
between 8 and 10 a.m.) in the respective groups starting from
week 8 until study end. Also starting from week 8 the respective
groups received a standard rat chow formulated with SLV329.
Chow was obtained from Altromin (Lage, Germany) in several
concentrations (0.0075%, 0.014%, and 0.05% SLV329) and fed to
the rats according to food intake. The target concentration was
5 mg/kg per day. Subsequently calculated mean intakes of the
groups were Con+SLV 5.4 mg/kg*d and Cir+SLV 5.1 mg/kg*d.
Blood was taken from the retro-orbital vein plexus 10 days and 4
weeks after the beginning of SLV329 treatment in 6 random
animals to measure the plasma concentration of SLV329. The
samples were analyzed as described above.
Body weight, water and food intake were measured weekly.
Systolic blood pressure and heart rate were measured in week 0
and 12 by tail plethysmography as described previously.[31] All
animals were placed in metabolism cages in week 0, 8 and 16.
Blood was taken from the retro-orbital vein plexus. The animals
were sacrificed after week 20 and liver and kidneys were excised.
Kidney samples were embedded in paraffin, cut into 3 mm sections
and submitted to periodic acid-Schiff, elastica and sirius red
staining. The extent of glomerulosclerosis, the renal media/lumen
ratio and renal interstitial fibrosis was determined as described
previously [32]. The extent of liver fibrosis was analyzed as in the
kidneys.
Alanine aminotransferase, bilirubin, albumin, creatinine, lipase
and creatine kinase were measured in plasma using commercially
available assays (ABX Pentra 400, Horiba Medical, Montpellier,
France). Creatinine, sodium, potassium and protein were mea-
sured in urine also using ABX Pentra 400.
Western blot
Western blot was performed in liver and kidney tissue for A1,
A2A,A 2B and A3 receptors using a method based on a previous
publication [33]. In brief, snap frozen liver and kidney samples
were pulverized in liquid nitrogen and dissolved in lysis buffer.
After incubation at room temperature for 10 min, the
suspension was centrifuged (16.200 g, 20uC, 45 min). Protein
concentrations were determined in the supernatant using the
Bradford method. Supernatant and Bradford solution (40 ml
each) were mixed in a well of a microtiter plate and incubated
for 10 min at room temperature on a shaker. Extinction was
then measured photometrically at 595 nm. The protein
concentration of each sample was calculated according to a
standard dilution series. The samples were diluted with lysis
buffer (5 g/l) to assure equal loading. Samples (23 mg protein
per lane) were separated by sodium dodecylsulfate polyacryl-
amide gel electrophoresis (10%, 80 V for 30 min, then 110 V)
and semi-dry-blotted (1,5 mA/cm
2, 60 min) onto nitrocellulose
membranes. Ponceau staining of membranes confirmed equal
loading of proteins. Membranes were blocked with 5% skim
milk and incubated overnight with primary rabbit antibodies
directed against A1R (0.025%, Sigma-Aldrich, Munich, Ger-
many), A2AR (0.1%, Millipore, Schwalbach, Germany), A2BR
(0.1%, Millipore), A3R (0.2%, Millipore), and beta-actin for
normalization (0.0025%, Sigma-Aldrich). The specificity of the
antibodies has been documented by the manufacturers and was
not tested again in this study. After extensive washing blots were
incubated with a horseradish peroxidase-linked anti-rabbit IgG
(60 min, 0.0001%, Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Immunoreactive bands were detected using an enhanced
chemiluminescence system and were subsequently quantified
with the AlphaEaseFC software (Alpha Innotech, San Leandro,
CA, USA). The values thus obtained were corrected for different
conditions between single runs, using a standard dilution series
that was run on each gel. Results of adenosine receptors were
then normalized to beta-actin.
Statistical analysis
Data was analyzed with SPSS 17.0 (SSPS Inc., Chicago, IL,
USA). The nonparametric Kruskal-Wallis and the Mann-Whit-
ney-U test were used to detect significant differences between
groups of interest. Mortality rates were estimated by the Kaplan-
Meier method and compared by log-rank test.
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